OPRX PE Ratio & Valuation,Is OPRX Overvalued

OPRX Relative Valuation

OPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OPRX is overvalued; if below, it's undervalued.

Historical Valuation

OptimizeRx Corp (OPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 18.97 is considered Undervalued compared with the five-year average of 60.45. The fair price of OptimizeRx Corp (OPRX) is between 16.07 to 58.66 according to relative valuation methord. Compared to the current price of 13.38 USD , OptimizeRx Corp is Undervalued By 16.76%.

Relative Value

Fair Zone

16.07-58.66

Current Price：13.38

16.76%

Undervalued

18.97

14.62

EV/EBITDA

OptimizeRx Corp. (OPRX) has a current EV/EBITDA of 14.62. The 5-year average EV/EBITDA is 54.85. The thresholds are as follows: Strongly Undervalued below -40.15, Undervalued between -40.15 and 7.35, Fairly Valued between 102.35 and 7.35, Overvalued between 102.35 and 149.85, and Strongly Overvalued above 149.85. The current Forward EV/EBITDA of 14.62 falls within the Historic Trend Line -Fairly Valued range.

52.76

EV/EBIT

OptimizeRx Corp. (OPRX) has a current EV/EBIT of 52.76. The 5-year average EV/EBIT is 131.63. The thresholds are as follows: Strongly Undervalued below -593.08, Undervalued between -593.08 and -230.73, Fairly Valued between 493.99 and -230.73, Overvalued between 493.99 and 856.35, and Strongly Overvalued above 856.35. The current Forward EV/EBIT of 52.76 falls within the Historic Trend Line -Fairly Valued range.

2.18

OptimizeRx Corp. (OPRX) has a current PS of 2.18. The 5-year average PS is 6.00. The thresholds are as follows: Strongly Undervalued below -5.00, Undervalued between -5.00 and 0.50, Fairly Valued between 11.50 and 0.50, Overvalued between 11.50 and 17.00, and Strongly Overvalued above 17.00. The current Forward PS of 2.18 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

OptimizeRx Corp. (OPRX) has a current P/OCF of 0.00. The 5-year average P/OCF is 56.13. The thresholds are as follows: Strongly Undervalued below -164.69, Undervalued between -164.69 and -54.28, Fairly Valued between 166.55 and -54.28, Overvalued between 166.55 and 276.96, and Strongly Overvalued above 276.96. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

OptimizeRx Corp. (OPRX) has a current P/FCF of 0.00. The 5-year average P/FCF is 75.84. The thresholds are as follows: Strongly Undervalued below -160.03, Undervalued between -160.03 and -42.10, Fairly Valued between 193.77 and -42.10, Overvalued between 193.77 and 311.71, and Strongly Overvalued above 311.71. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

OptimizeRx Corp (OPRX) has a current Price-to-Book (P/B) ratio of 2.04. Compared to its 3-year average P/B ratio of 1.73 , the current P/B ratio is approximately 17.52% higher. Relative to its 5-year average P/B ratio of 3.94, the current P/B ratio is about -48.24% higher. OptimizeRx Corp (OPRX) has a Forward Free Cash Flow (FCF) yield of approximately 4.72%. Compared to its 3-year average FCF yield of 0.93%, the current FCF yield is approximately 407.30% lower. Relative to its 5-year average FCF yield of 0.66% , the current FCF yield is about 612.61% lower.

2.04

P/B

Median3y

1.73

Median5y

3.94

4.72

FCF Yield

Median3y

0.93

Median5y

0.66

Competitors Valuation Multiple

The average P/S ratio for OPRX's competitors is 3.15, providing a benchmark for relative valuation. OptimizeRx Corp Corp (OPRX) exhibits a P/S ratio of 2.18, which is -30.71% above the industry average. Given its robust revenue growth of 22.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of OPRX increased by 174.90% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.03K to 7.29K.

The secondary factor is the Revenue Growth, contributed 22.33%to the performance.

Overall, the performance of OPRX in the past 1 year is driven by P/E Change. Which is more unsustainable.

22.33%

21.31M → 26.07M

Revenue Growth

-106.98%

-42.82 → 2.99

Margin Expansion

259.55%

2.03K → 7.29K

P/E Change

174.90%

4.86 → 13.36

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is OptimizeRx Corp (OPRX) currently overvalued or undervalued?

What is OptimizeRx Corp (OPRX) fair value?

OPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of OptimizeRx Corp (OPRX) is between 16.07 to 58.66 according to relative valuation methord.

How does OPRX's valuation metrics compare to the industry average?

What is the current P/B ratio for OptimizeRx Corp (OPRX) as of Dec 15 2025?

As of Dec 15 2025, OptimizeRx Corp (OPRX) has a P/B ratio of 2.04. This indicates that the market values OPRX at 2.04 times its book value.

What is the current FCF Yield for OptimizeRx Corp (OPRX) as of Dec 15 2025?

As of Dec 15 2025, OptimizeRx Corp (OPRX) has a FCF Yield of 4.72%. This means that for every dollar of OptimizeRx Corp’s market capitalization, the company generates 4.72 cents in free cash flow.

What is the current Forward P/E ratio for OptimizeRx Corp (OPRX) as of Dec 15 2025?

As of Dec 15 2025, OptimizeRx Corp (OPRX) has a Forward P/E ratio of 18.97. This means the market is willing to pay $18.97 for every dollar of OptimizeRx Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for OptimizeRx Corp (OPRX) as of Dec 15 2025?

As of Dec 15 2025, OptimizeRx Corp (OPRX) has a Forward P/S ratio of 2.18. This means the market is valuing OPRX at $2.18 for every dollar of expected revenue over the next 12 months.

OPRX Valuation